Form 4: Edwards Lifesciences CEO Bernard Zovighian Reports Changes in Beneficial Ownership

CEO Bernard Zovighian reports transactions involving Edwards Lifesciences Corp stock, including acquisitions, disposals, and option exercises, pursuant to a pre-arranged trading plan.

Summary

• On May 3, 2025, Bernard Zovighian disposed of 527 shares of Edwards Lifesciences common stock at a price of $75.65.
• On May 4, 2025, Zovighian disposed of 543 shares at $75.65.
• On May 5, 2025, Zovighian acquired 7,462 shares through the exercise of employee stock options at $45.2767.
• Also on May 5, 2025, Zovighian disposed of 1,482 shares as a gift.
• Zovighian disposed of 5,980 shares on May 5, 2025, at a weighted average price of $74.9125, with individual trades ranging from $74.67 to $75.15.
• On May 6, 2025, Zovighian disposed of 1,036 shares as a gift.
• Zovighian also reported acquisitions of common stock through a trust and the company's 401(k) plan.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on December 6, 2024.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are part of a pre-planned trading strategy, so they don't necessarily reflect a change in the executive's outlook on the company. The exercise of options is a positive sign, but the sales offset this.

Positives

• The exercise of stock options indicates confidence in the company's future performance.

Negatives

• The disposal of shares, even partially through gifts, could be interpreted negatively by some investors.

Risks

• Executive stock sales can sometimes be perceived as a lack of confidence in the company's future prospects, although this is mitigated by the pre-arranged trading plan.

Future Outlook

The document does not contain specific forward-looking statements, but the ongoing transactions under the Rule 10b5-1 plan suggest a continuation of trading activity.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are often scrutinized by investors for insights into management's perspective on the company's valuation and future prospects. Rule 10b5-1 plans are frequently used to mitigate concerns about insider trading.

Comparison to Industry Standards

• Executive compensation and stock ownership are closely monitored in the medical device industry.
• Companies like Medtronic, Abbott, and Boston Scientific also have executives who regularly trade company stock under similar pre-arranged plans.
• The size and frequency of these transactions are generally in line with industry norms for CEOs of large, publicly traded companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders' perception of the company, but the pre-arranged nature of the trades should mitigate any significant concerns.

Key Dates

Keywords

Form 4, beneficial ownership, stock options, Rule 10b5-1, Edwards Lifesciences, Zovighian, stock, trading plan